In The News
Featured Evidence
- April 28, 2024
CGM Improves Glycemic Control and Reduces CVD Risk in Non-Insulin-Treated T2D
Learn MoreAmong 47 patients enrolled in a cardiovascular disease (CVD) outpatient program, CGM use was associated with improved glycemic and cardiometabolic outcomes. In the two-phase crossover study, participants were required to have T2D not treated with insulin therapy, an HbA1c >7%, and an obesity classification (BMI ≥30 kg/m2). Through 90 days of follow-up, CGM use was...
- April 15, 2024
CGM Associated with Reduced Cost and Health Care Resource Utilization in Intensive Insulin-Treated T2D
Learn More
- November 11, 2022
WISDM Trial: Hypoglycemia Avoidance Associated with rtCGM Sustained Out to 12 Months in Older Adults
Learn More
Latest Expert Interview
Addressing Disparities in Care with Evidence-Based Utilization of Diabetes Technology
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
Watch Now View All InterviewsValue of CGM
more patients using rtCGM achieve HEDIS-compliant HbA1C<8% compared with BGM 1 1. Karter AJ, et al. JAMA. 2021;325:2273-2284. doi: 10.1001/jama.2021.6530.
of patients report modifying lifestyle choices due to rtCGM feedback 2 2. Ehrhardt N, et al. Clin Diabetes. 2020;38:126-131. doi: 10.2337/cd19-0037.
in PMPM savings in T2 diabetes related costs according to claims analyses of rtCGM users
3, 4
3. Norman GJ, et al. Diabetes Technol Ther.
2022;24:520-524. doi: 10.1089/dia.2021.0525.
4. Isaacson B, et al. J Diabetes Sci Technol.
2022;16:383-389. doi: 10.1177/1932296820955228.